Receptor-binding domain as a target for developing SARS vaccines.
Identifieur interne : 001114 ( PubMed/Checkpoint ); précédent : 001113; suivant : 001115Receptor-binding domain as a target for developing SARS vaccines.
Auteurs : Xiaojie Zhu [République populaire de Chine] ; Qi Liu ; Lanying Du ; Lu Lu ; Shibo JiangSource :
- Journal of thoracic disease [ 2072-1439 ] ; 2013.
Abstract
A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.
DOI: 10.3978/j.issn.2072-1439.2013.06.06
PubMed: 23977435
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23977435Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Receptor-binding domain as a target for developing SARS vaccines.</title><author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23977435</idno><idno type="pmid">23977435</idno><idno type="doi">10.3978/j.issn.2072-1439.2013.06.06</idno><idno type="wicri:Area/PubMed/Corpus">001141</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001141</idno><idno type="wicri:Area/PubMed/Curation">001141</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001141</idno><idno type="wicri:Area/PubMed/Checkpoint">001114</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001114</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Receptor-binding domain as a target for developing SARS vaccines.</title><author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></analytic><series><title level="j">Journal of thoracic disease</title><idno type="ISSN">2072-1439</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV. </div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23977435</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>5 Suppl 2</Volume><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Receptor-binding domain as a target for developing SARS vaccines.</ArticleTitle><Pagination><MedlinePgn>S142-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3978/j.issn.2072-1439.2013.06.06</ELocationID><Abstract><AbstractText>A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaojie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Lanying</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Lu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI098775</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Virus</Keyword><Keyword MajorTopicYN="N">receptor-binding domain (RBD)</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23977435</ArticleId><ArticleId IdType="doi">10.3978/j.issn.2072-1439.2013.06.06</ArticleId><ArticleId IdType="pii">jtd-05-S2-S142</ArticleId><ArticleId IdType="pmc">PMC3747534</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2012 Oct 4;490(7418):20</Citation><ArticleIdList><ArticleId IdType="pubmed">23038444</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Jan 15;180(2):948-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18178835</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2012 Dec;11(12):1405-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23252385</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 May 16;368(20):1888-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23577628</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2007 May 10;361(2):304-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17210170</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Mar 14;495(7440):176-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23486053</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2008 Feb;18(2):290-301</Citation><ArticleIdList><ArticleId IdType="pubmed">18227861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2013 Aug;67(2):130-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23583636</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jun 13;368(24):2277-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23697469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 1;181(9):6337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18941225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Nov 19;279(47):49414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15345712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2010 Apr;23(2):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20374001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Mar 20;26(13):1644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18289745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22311359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Aug 19;280(33):29588-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15980414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2013 Oct;67(4):348-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23685240</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2013 Jun;15(6-7):432-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23628410</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Oct;10(10):1774-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15504263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2832-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17092615</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Sep 15;353(1):6-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16793110</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2013 May;66(5):464-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23266463</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19422787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001114 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001114 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23977435
|texte= Receptor-binding domain as a target for developing SARS vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23977435" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |